Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer

Byeon, Hyeong Jun; Choi, Seong Ho; Choi, Ji Su; Kim, In-Soo; Shin, Beom Soo; Lee, Eun Seong; Park, Eun-Seok; Lee, Kang Choon; Youn, Yu Seok

doi:10.1016/j.actbio.2013.08.046

Cited by 41 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the PLGA MSs containing PEG-TRAIL retained significant apoptotic activity, along with improved release property. We have previously demonstrated that PEG-TRAIL has significantly greater physicochemical stability than native TRAIL, 27 and such increased stability by PEGylation might be responsible for well-retained in vitro bioactivity of PEG-TRAIL inside PLGA MSs. Actually, all of the released medium obtained from PEG-TRAIL PLGA MSs until 7 days was found to have significant apoptotic and cytotoxic activity (~70%) against pancreatic tumor cells.…”

Section: Discussionmentioning

confidence: 99%

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Byeon

Kim

Choi

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

The aim of the current study was to investigate the antitumor potential of poly (D,L-lactic- co -glycolic acid) microspheres (PLGA MSs) containing polyethylene glycol (PEG)-conjugated (PEGylated) tumor necrosis factor–related apoptosis-inducing ligand (PEG-TRAIL). PEG-TRAIL PLGA MSs were prepared by using a water-in-oil-in-water double-emulsion method, and the apoptotic activities of supernatants released from the PLGA MSs at days 1, 3, and 7 were examined. The antitumor effect caused by PEG-TRAIL PLGA MSs was evaluated in pancreatic Mia Paca-2 cell-xenografted mice. PEG-TRAIL PLGA MS was found to be spherical and 14.4±1.06 μm in size, and its encapsulation efficiency was significantly greater than that of TRAIL MS (85.7%±4.1% vs 43.3%±10.9%, respectively). The PLGA MS gradually released PEG-TRAIL for 14 days, and the released PEG-TRAIL was shown to have clear apoptotic activity in Mia Paca-2 cells, whereas TRAIL released after 1 day had a negligible activity. Finally, PEG-TRAIL PLGA MS displayed remarkably greater antitumor efficacy than blank or TRAIL PLGA MS in Mia Paca-2 cell-xenografted mice in terms of tumor volume and weight, apparently due to increased stability and well-retained apoptotic activity of PEG-TRAIL in PLGA MS. We believe that this PLGA MS system, combined with PEG-TRAIL, should be considered a promising candidate for treating pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Byeon

Kim

Choi

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cytotoxicities of different types of HSA-NPs (Blank, Dox, TRAIL, TRAIL/Dox) to H226 cells, a human lung squamous cell carcinoma cell-line, were evaluated using a modification of previously described methods [11,25,30]. Briefly, H226 cells (ATCC, USA) were cultivated in RPMI1640 (ATCC) containing 10% (v/v) fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin (Gibco) in a 5% CO 2 /95% air incubator at 37°C.…”

Section: Cytotoxicity Assessment Of Hsa-nps In H226 Cellsmentioning

confidence: 99%

“…The slides were then rinsed three times with DPBS, dried and reacted with DAPI solution. Apoptotic H226 cells were analyzed by confocal laser scanning microscopy (CLSM) using an excitation wavelength of 450-490 nm and a detection wavelength of 520 nm, as described previously [25,30,31].…”

Section: Apoptotic Activity Assessments Of Hsa-nps Using H226 Cellsmentioning

confidence: 99%

Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

Choi

Byeon

Choi

et al. 2015

Journal of Controlled Release

Self Cite

132

View full text Add to dashboard Cite

“…It is interesting to note that PEGylated TRAIL has further been tested using a specific delivery system consisting of four-arm PEG cross-linked hyaluronic acid (HA) hydrogels. The results revealed that antitumor activity of TRAIL in mice xenografted with Mia Paca-2 was remarkably higher because of stability of PEGylated TRAIL in HA hydrogels (Byeon et al, 2014). Bae et al (2012) designed human serum albumin (HSA) nanoparticles with the surface modified by TRAIL and transferrin, and containing doxorubicin, which were demonstrated to have a significant in vitro killing activity against different cancer cell lines.…”

Section: The Role Of Nanotechnology On Antitumor Activity Of Trailmentioning

confidence: 99%

TRAIL Mediated Signaling in Pancreatic Cancer

Nogueira

Yaylım²,

Aamir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Research over the years has progressively shown substantial broadening of the tumor necrosis factor alpharelated apoptosis-inducing ligand (TRAIL)-mediated signaling landscape. Increasingly it is being realized that pancreatic cancer is a multifaceted and genomically complex disease. Suppression of tumor suppressors, overexpression of oncogenes, epigenetic silencing, and loss of apoptosis are some of the extensively studied underlying mechanisms. Rapidly accumulating in vitro and in vivo evidence has started to shed light on the resistance mechanisms in pancreatic cancer cells. More interestingly a recent research has opened new horizons of miRNA regulation by DR5 in pancreatic cancer cells. It has been shown that DR5 interacts with the core microprocessor components Drosha and DGCR8, thus impairing processing of primary let-7. Xenografting DR5 silenced pancreatic cancer cells in SCID-mice indicated that there was notable suppression of tumor growth. There is a paradigm shift in our current understanding of TRAIL mediated signaling in pancreatic cancer cells that is now adding new layers of concepts into the existing scientific evidence. In this review we have attempted to provide an overview of recent advances in TRAIL mediated signaling in pancreatic cancer as evidenced byfindings of in vitro and in vivo analyses. Furthermore, we discuss nanotechnological advances with emphasis on PEG-TRAIL and four-arm PEG cross-linked hyaluronic acid (HA) hydrogels to improve availability of TRAIL at target sites.

show abstract

Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer

Cited by 41 publications

References 36 publications

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

TRAIL Mediated Signaling in Pancreatic Cancer

Contact Info

Product

Resources

About